Neutrophil elastase inhibitor POL6014

Polyphor's third product POL6014 is a novel, highly potent, selective and reversible inhibitor of human neutrophil elastase, a key target for the treatment of respiratory diseases like cystic fibrosis, alpha-1-antitrypsin deficiency or chronic obstructive pulmonary disease (COPD). In preclinical studies POL6014 inhibits the aggressive lung degrading enzyme neutrophil elastase in a highly potent, selective and competitive manner. After local application to the lung, high concentrations of POL6014 are retained in the lungs while the systemic exposure remains low, thus reducing the risk of adverse effects.

POL6014 has been shown to be highly efficacious in several animal models of respiratory diseases.

POL6014 is ready to enter IND enabling studies.

Polyphor is now seeking a strong partner to build an alliance to develop and commercialize POL6014 with an initial focus on alpha-1-antitrypsin deficiency and cystic fibrosis.